GlassScriptPhysician profile
Timothy D Miller
NPI 1346419355
$145,514.80
in general payments reported to CMS, 2019-2025
51 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,259 · 2020: $897 · 2021: $2,353 · 2022: $6,841 · 2023: $69K · 2024: $20K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119K · Food and Beverage: $10K · Travel and Lodging: $2,566 · Education: $1,160 · Consulting Fee: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $119,246.91 |
| Food and Beverage | $10,223.77 |
| Travel and Lodging | $2,565.87 |
| Education | $1,160.00 |
| Consulting Fee | $967.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $77,430.63 | 2022-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $29,207.71 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $16,747.66 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $9,326.21 | 2024-2025 | Zenpep, Vowst |
| Abbvie INC. | $3,574.72 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,728.14 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $958.76 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $905.31 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $545.07 | 2019-2025 | Livdelzi |
| Daiichi Sankyo INC. | $523.96 | 2019-2024 | Injectafer, Vanflyta |
| Intercept Pharmaceuticals, INC. | $514.15 | 2019-2024 | Ocaliva |
| Boston Scientific Corporation | $411.76 | 2019-2024 | Radial Jaw 4 |
| Nuvasive, INC. | $400.42 | 2023 | Alif |
| Ipsen Biopharmaceuticals, INC | $293.28 | 2019-2025 | Iqirvo, Bylvay, Onivyde |
| Astrazeneca Pharmaceuticals LP | $250.05 | 2019-2025 | Imfinzi, Calquence, Lynparza |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $248.01 | 2020-2021 | |
| Ardelyx, INC. | $245.69 | 2022-2024 | Ibsrela |
| Pfizer INC. | $212.47 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $196.95 | 2024-2025 | Tremfya, Stelara, Remicade |
| Mallinckrodt Hospital Products INC. | $188.70 | 2024-2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $176.61 | 2019-2024 | Dificid |
| Qol Medical, LLC | $150.61 | 2022-2024 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $120.73 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $113.02 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $111.27 | 2023-2025 | Omvoh |
| Intuitive Surgical, INC. | $103.26 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $101.67 | 2019-2020 | |
| Genzyme Corporation | $85.65 | 2019-2025 | |
| Ucb, INC. | $77.58 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $63.97 | 2021-2023 | |
| Celgene Corporation | $52.59 | 2021-2022 | |
| Redhill Biopharma INC. | $44.60 | 2020-2023 | Talicia |
| Amgen INC. | $36.85 | 2021-2025 | Uplizna |
| Allergan, INC. | $36.41 | 2019 | |
| Medtronic, INC. | $34.07 | 2023-2024 | Interstim, Gi Genius |
| Astellas Pharma US INC | $30.41 | 2019-2020 | |
| Axonics, INC. | $29.93 | 2021 | |
| Servier Pharmaceuticals LLC | $24.60 | 2024 | |
| Shire North American Group INC | $24.24 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.38 | 2021 | |
| Genentech USA, INC. | $23.29 | 2024 | Lunsumio, Polivy |
| Alcresta Therapeutics, INC. | $20.15 | 2023 | Relizorb |
| Seagen INC. | $19.54 | 2020 | |
| Novo Nordisk INC | $18.71 | 2025 | Wegovy |
| Pharmacosmos Therapeutics INC. | $18.63 | 2022 | |
| Acacia Pharma INC | $16.46 | 2021 | |
| Glaxosmithkline, LLC. | $14.32 | 2019 | |
| Organon LLC | $12.65 | 2022 | |
| Eisai INC. | $12.23 | 2019 | |
| Endogastric Solutions, INC | $7.72 | 2024 | Esophyx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$35,647.21 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.